JERUSALEM, October 30 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that its Chief Executive Officer, Mr. Nadav Kidron, will be giving a company presentation at the 10th Annual Rodman & Renshaw Healthcare Conference at New York City's Palace Hotel on November 11. Mr. Kidron is scheduled to present from 4:05 - 4:30 in the Kennedy II Ballroom, located on the 4th floor of the hotel.
"The Rodman & Renshaw Conference will give Oramed an important platform to present the accomplishments we have achieved in our development of an oral insulin capsule and our unique position as a technology pioneer in the field of oral delivery solutions," said Kidron.
For more information about Rodman & Renshaw and the upcoming conference, please visit http://www.rodmanandrenshaw.com/conferences.
For more information about Oramed Pharmaceuticals, please visit http://www.oramed.com.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the
risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays
in obtaining regulatory approval for our product candidates; competition
from other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its research,
development and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a comprehensive
list of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no
obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Ruder Finn Israel for Oramed
|SOURCE Oramed Pharmaceticals|
Copyright©2008 PR Newswire.
All rights reserved